KRAS and neoplasm: Thota et al. (2021) found that APC and TP53 mutations can predict cetuximab sensitivity across consensus molecular subtypes, based on an analysis of multiple CRC tumor/PDX/cell line datasets.56 In our HNSCC PCT, all of the PDXs were wild-type KRAS, and we found that TP53 mutation was related to the sensitivity of cetuximab: the mutation rate of TP53 in the sensitive group was 100% but was only 62.5% in the intrinsic resistance group.